DOI QR코드

DOI QR Code

Questionable Reliability of Malondialdehyde to Measure Oxidative Stress in Sjögren's Syndrome: Preliminary Study

  • Lee, Kyung-Eun (Department of Oral Medicine, Institute of Oral Bioscience, School of Dentistry, Jeonbuk National University) ;
  • Jung, Won (Department of Oral Medicine, Institute of Oral Bioscience, School of Dentistry, Jeonbuk National University) ;
  • Suh, Bong-Jik (Department of Oral Medicine, Institute of Oral Bioscience, School of Dentistry, Jeonbuk National University) ;
  • Cha, Seunghee (Department of Oral and Maxillofacial Diagnostic Sciences, University of Florida College of Dentistry)
  • Received : 2020.11.24
  • Accepted : 2020.12.16
  • Published : 2020.12.30

Abstract

Purpose: To investigate the expression of malondialdehyde (MDA), lipid peroxidation marker for oxidative stress (OS), in autoimmune Sjögren's syndrome (SjS) by utilizing the SjS-prone C57BL/6.NOD-Aec1Aec2 (B6DC) mouse and the SjS patient plasma samples. Methods: The MDA concentrations in the lysates of the submandibular gland, liver, and serum samples from the SjS-prone B6DC mouse model were compared with those from the C57BL/6J as a control. A thiobarbituric acid reactive substance (TBARS) assay kit was used to measure MDA. Plasma samples from five SjS patients and five control subjects were also evaluated. Results: The MDA concentrations in experimental animals and controls were not significantly different. There were no significant differences between the plasma of SjS patients and of controls. Conclusions: The expression of MDA was investigated in the organs from the SjS-prone B6DC mouse for the first time and in the plasma samples of SjS patients. No significant differences were observed between SjS and control samples when MDA was the target molecule with the TBARS assay. MDA may not be a reliable marker to measure OS contrary to the published studies involving OS of SjS.

Keywords

References

  1. Fox RI. Sjogren's syndrome. Lancet 2005;366:321-331. https://doi.org/10.1016/S0140-6736(05)66990-5
  2. Bayetto K, Logan RM. Sjogren's syndrome: a review of aetiology, pathogenesis, diagnosis and management. Aust Dent J 2010;55 Suppl 1:39-47. https://doi.org/10.1111/j.1834-7819.2010.01197.x
  3. Park YS, Gauna AE, Cha S. Mouse models of primary Sjogren's syndrome. Curr Pharm Des 2015;21:2350-2364. https://doi.org/10.2174/1381612821666150316120024
  4. Nguyen CQ, Peck AB. Unraveling the pathophysiology of Sjogren syndrome-associated dry eye disease. Ocul Surf 2009;7:11-27. https://doi.org/10.1016/S1542-0124(12)70289-6
  5. Li X, Golden J, Faustman DL. Faulty major histocompatibility complex class II I-E expression is associated with autoimmunity in diverse strains of mice. Autoantibodies, insulitis, and sialadenitis. Diabetes 1993;42:1166-1172. https://doi.org/10.2337/diabetes.42.8.1166
  6. Wicker LS, Todd JA, Prins JB, Podolin PL, Renjilian RJ, Peterson LB. Resistance alleles at two non-major histocompatibility complex-linked insulin-dependent diabetes loci on chromosome 3, Idd3 and Idd10, protect nonobese diabetic mice from diabetes. J Exp Med 1994;180:1705-1713. https://doi.org/10.1084/jem.180.5.1705
  7. Killedar SJ, Eckenrode SE, McIndoe RA, et al. Early pathogenic events associated with Sjogren's syndrome (SjS)-like disease of the NOD mouse using microarray analysis. Lab Invest 2006;86:1243-1260. https://doi.org/10.1038/labinvest.3700487
  8. Robinson CP, Yamamoto H, Peck AB, Humphreys-Beher MG. Genetically programmed development of salivary gland abnormalities in the NOD (nonobese diabetic)-scid mouse in the absence of detectable lymphocytic infiltration: a potential trigger for sialoadenitis of NOD mice. Clin Immunol Immunopathol 1996;79:50-59. https://doi.org/10.1006/clin.1996.0050
  9. Robinson CP, Yamachika S, Bounous DI, et al. A novel NOD-derived murine model of primary Sjogren's syndrome. Arthritis Rheum 1998;41:150-156. https://doi.org/10.1002/1529-0131(199801)41:1<150::AID-ART18>3.0.CO;2-T
  10. Lam GY, Huang J, Brumell JH. The many roles of NOX2 NADPH oxidase-derived ROS in immunity. Semin Immunopathol 2010;32: 415-430. https://doi.org/10.1007/s00281-010-0221-0
  11. Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol 2014;24:R453-R462. https://doi.org/10.1016/j.cub.2014.03.034
  12. Mao X, Gu C, Chen D, Yu B, He J. Oxidative stress-induced diseases and tea polyphenols. Oncotarget 2017;8:81649-81661. https://doi.org/10.18632/oncotarget.20887
  13. Kurien BT, Scofield RH. Autoimmunity and oxidatively modified autoantigens. Autoimmun Rev 2008;7:567-573. https://doi.org/10.1016/j.autrev.2008.04.019
  14. Norheim KB, Jonsson G, Harboe E, Hanasand M, Goransson L, Omdal R. Oxidative stress, as measured by protein oxidation, is increased in primary Sjogren's syndrome. Free Radic Res 2012; 46:141-146. https://doi.org/10.3109/10715762.2011.645206
  15. Pagano G, Castello G, Pallardo FV. Sjogren's syndrome-associated oxidative stress and mitochondrial dysfunction: prospects for chemoprevention trials. Free Radic Res 2013;47:71-73. https://doi.org/10.3109/10715762.2012.748904
  16. Wakamatsu TH, Dogru M, Matsumoto Y, et al. Evaluation of lipid oxidative stress status in Sjogren syndrome patients. Invest Ophthalmol Vis Sci 2013;54:201-210. https://doi.org/10.1167/iovs.12-10325
  17. Ayala A, Munoz MF, Arguelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev 2014;2014:360438. https://doi.org/10.1155/2014/360438
  18. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-558. https://doi.org/10.1136/ard.61.6.554
  19. Ryo K, Yamada H, Nakagawa Y, et al. Possible involvement of oxidative stress in salivary gland of patients with Sjogren's syndrome. Pathobiology 2006;73:252-260. https://doi.org/10.1159/000098211
  20. Kurimoto C, Kawano S, Tsuji G, et al. Thioredoxin may exert a protective effect against tissue damage caused by oxidative stress in salivary glands of patients with Sjogren's syndrome. J Rheumatol 2007;34:2035-2043.
  21. Cejkova J, Ardan T, Simonova Z, et al. Nitric oxide synthase induction and cytotoxic nitrogen-related oxidant formation in conjunctival epithelium of dry eye (Sjogren's syndrome). Nitric Oxide 2007;17:10-17. https://doi.org/10.1016/j.niox.2007.04.006
  22. Jiang S, Hu L, Ping L, Sun F, Wang X. Glutathione protects against hepatic injury in a murine model of primary Sjogren's syndrome. Bosn J Basic Med Sci 2016;16:227-231. https://doi.org/10.17305/bjbms.2016.1059
  23. Spiteller G. Linoleic acid peroxidation--the dominant lipid peroxidation process in low density lipoprotein--and its relationship to chronic diseases. Chem Phys Lipids 1998;95:105-162. https://doi.org/10.1016/S0009-3084(98)00091-7
  24. Yamauchi Y, Matsuno T, Omata K, Satoh T. Relationship between hyposalivation and oxidative stress in aging mice. J Clin Biochem Nutr 2017;61:40-46. https://doi.org/10.3164/jcbn.16-79
  25. McGrath LT, McGleenon BM, Brennan S, McColl D, McILroy S, Passmore AP. Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. QJM 2001;94:485-490. https://doi.org/10.1093/qjmed/94.9.485
  26. Vessby J, Basu S, Mohsen R, Berne C, Vessby B. Oxidative stress and antioxidant status in type 1 diabetes mellitus. J Intern Med 2002;251:69-76. https://doi.org/10.1046/j.1365-2796.2002.00927.x
  27. Frijhoff J, Winyard PG, Zarkovic N, et al. Clinical relevance of biomarkers of oxidative stress. Antioxid Redox Signal 2015;23: 1144-1170. https://doi.org/10.1089/ars.2015.6317
  28. Giera M, Lingeman H, Niessen WM. Recent advancements in the LC- and GC-based analysis of malondialdehyde (MDA): a brief overview. Chromatographia 2012;75:433-440. https://doi.org/10.1007/s10337-012-2237-1
  29. Tsikas D. Assessment of lipid peroxidation by measuring malondialdehyde (MDA) and relatives in biological samples: analytical and biological challenges. Anal Biochem 2017;524:13-30. https://doi.org/10.1016/j.ab.2016.10.021
  30. Del Rio D, Stewart AJ, Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis 2005;15:316-328. https://doi.org/10.1016/j.numecd.2005.05.003
  31. Knight JA, Pieper RK, McClellan L. Specificity of the thiobarbituric acid reaction: its use in studies of lipid peroxidation. Clin Chem 1988;34:2433-2438. https://doi.org/10.1093/clinchem/34.12.2433
  32. Domijan AM, Ralic J, Radic Brkanac S, Rumora L, Zanic-Grubisic T. Quantification of malondialdehyde by HPLC-FL - application to various biological samples. Biomed Chromatogr 2015;29:41-46. https://doi.org/10.1002/bmc.3361
  33. Khoubnasabjafari M, Ansarin K, Jouyban A. Reliability of malondialdehyde as a biomarker of oxidative stress in psychological disorders. Bioimpacts 2015;5:123-127. https://doi.org/10.15171/bi.2015.20
  34. Breusing N, Grune T, Andrisic L, et al. An inter-laboratory validation of methods of lipid peroxidation measurement in UVA-treated human plasma samples. Free Radic Res 2010;44:1203-1215. https://doi.org/10.3109/10715762.2010.499907
  35. Mateos R, Lecumberri E, Ramos S, Goya L, Bravo L. Determination of malondialdehyde (MDA) by high-performance liquid chromatography in serum and liver as a biomarker for oxidative stress. Application to a rat model for hypercholesterolemia and evaluation of the effect of diets rich in phenolic antioxidants from fruits. J Chromatogr B Analyt Technol Biomed Life Sci 2005;827:76-82. https://doi.org/10.1016/j.jchromb.2005.06.035
  36. Tsikas D, Rothmann S, Schneider JY, et al. Development, validation and biomedical applications of stable-isotope dilution GC-MS and GC-MS/MS techniques for circulating malondialdehyde (MDA) after pentafluorobenzyl bromide derivatization: MDA as a biomarker of oxidative stress and its relation to 15(S)-8-isoprostaglandin F2α and nitric oxide (NO). J Chromatogr B Analyt Technol Biomed Life Sci 2016;1019:95-111. https://doi.org/10.1016/j.jchromb.2015.10.009